Group 1 - The core viewpoint of the article highlights the recent stock performance of CSPC Pharmaceutical Group, which saw a decline of 2.75% to HKD 10.62 per share, with a trading volume of HKD 3.02 billion [1] - CSPC Pharmaceutical Group is a Hong Kong-listed pharmaceutical company focused on the production of finished drugs and active pharmaceutical ingredients, with a strategic emphasis on innovative drugs targeting various therapeutic areas including neurological diseases, oncology, anti-infection, and cardiovascular diseases [1] - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of HKD 70.15 billion and a net profit of HKD 14.78 billion [1] Group 2 - CSPC Pharmaceutical Group is scheduled to disclose its interim report for the fiscal year 2025 on August 22 [2]
石药集团(01093)下跌2.75%，报10.62元/股